Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Patent
1994-09-12
1996-12-17
Davenport, Avis M.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
530314, 530328, A61K 3800, A61K 3804, C07K 500, C07K 700
Patent
active
055853552
ABSTRACT:
The permeability of the blood-ocular barrier to therapeutic or diagnostic agents in the bloodstream of a host is increased by administering a permeabilizer peptide, preferably bradykinin or a bradykinin analogue, into the bloodstream of a host. The invention provides methods of treatment or diagnosis of ocular diseases by administration of a permeabilizer peptide, such as permeabilizer A-7, in combination with a therapeutic or diagnostic agent.
REFERENCES:
patent: 4923963 (1990-05-01), Stewart et al.
patent: 5112596 (1992-05-01), Malfroy-Camine
patent: 5162497 (1992-11-01), Coy et al.
patent: 5268164 (1993-12-01), Kozarich et al.
Cole, D. F., Exp. Eye. Res., vol. 19, No. 6, pp. 591-607, 1974.
Kuppersmith et al., Implications of the Blood-Brain-Barrier and its Manipulation, E. A. Neuwelt, M.D. ed., pp. 369-390, 1989.
Greenwood, J., "Mechanisms of blood-brain barrier breakdown", Neuroradiology, 33(2) : 95-100 (1991).
Cole, D. F., "The Site of Breakdown of the Blood-Aqueous Barrier under the Influence of Vaso-dilator Drugs", Exp. Eye Res., 19(6) : 591-607 (1974).
Bynke, G., et al., "Bradykinin Contracts The Pupillary Sphincter and Evokes Ocular Inflammation Through Release of Neuronal Substance P", Eur. J. Pharmacol., 91(4) : 469-475 (Abstract only) (1983).
Kaufman, P. L., et al., "Effect of Serotonin, Histamine and Bradykinin on Outflow Facility Following Ciliary Muscle Retrodisplacement in the Cynomolgus Monkey", Exp. Eye Res., 35(2) : 91-199 (Abstract only) (1982).
Ferrari-Dileo, G., et al., "Angiotensin-Converting Enzyme in Bovine, Feline, and Human Ocular Tissues", Invest. Ophthalmol. Vis. Sci., 29(6) : 876-881 (Abstract only) (1988).
Yokoyama, K., et al., "Implication of Polymodal Receptor Activities in Intraocular Pressure Elevation By Neurogenic Inflammation", Jpn. J. Ophthalmol., 34(2) : 245-255 (Abstract only) (1990).
Kupersmith, M. J. and Shakib, M., "The Blood-Ocular Barrier". In Implications of the Blood-Brain Barrier and Its Manipulation, E. A. Neuwelt, M.D. ed. (NY: Plenum Publishing ), pp. 369-390 (1989).
Bradbury, M. W. B. and Lightman, S. L., "The Blood-Brain Interface", Eye, 4:249-254 (1990).
Alm, A., "Ocular Circulation". In Adlers Physiology of the Eye 9th Ed., W. M. Hart, Jr., ed. (St. Louis, MO: Mosbey-Year Book Inc.), pp. 198-227 (1992).
Stewart, P. A. and Tuor, U. I., "Blood-Eye Barriers in the Rat: Correlation of Ultrastructure With Function", J. of Comparative Neurol., 340:566-576 (1994).
Gratton et al., J. Physiol., vol. 446, p. 508P, Nov. 1991.
Mataix Sanjuan et al., Chemical Abstrat, vol. 119, p. 3, 1993, Ab No.: 85149d.
Zlokovic, B. V. et al., "An In Situ Perfused Guinea-pig Eye Model for Blood-Ocular Transport Studies: Application to Amino Acids", Exp. Eye Res., 54:471-477 (1992).
Novack, G. D. et al., "The Blood-Aqueous and Blood-Brain Barriers to Permeability", Am. J. of Ophthalmology (Editorial) 105(4): 412-416 (Apr. 1988).
Frank, J. A. et al., "Opening of Blood-Ocular Barrier Demonstrated by Contrast-Enhanced MR Imaging", J. of Computer Assisted Tomography 10(6): 912-916 (Nov.-Dec. 1986).
Enea, N. A. et al., "Histamine H.sub.1 Receptors Mediate Increased Blood -Retinal Barrier Permeability in Experimental Diabetes", Arch Ophthalmol 107:270-274 (Feb. 1989).
BenEzra, D. et al., "Ocular Penetration of Cyclosporine A in the Rat Eye", Arch Ophthalmol 108:584-587 (Apr. 1990).
Kyle, D. J. et al., "Probing the Bradykinin Receptor: Mapping the Geometric Topography Using Ethers of Hydroxyproline in Novel Peptides", J. Med. Chem. 34(8) : 2649-2653 (1991).
Drapeau, G. et al., "Synthesis of Bradykinin Analogs", Methods in Enzymology 163:263-272 (1988).
Kyle, D. J. et al., "Design and Conformational Analysis of Several Highly Potent Bradykinin Receptor Antagonists", J. Med. Chem., 34(3) : 1230 -1233 (1991).
Unterberg, A. et al., "The Kallikrein-Kinin System as Mediator in Vasogenic Brain Edema Part I: Cerebral Exposure to Bradykinin and Plasma", J. Neurosurg. 61:87-96 (Jul. 1984).
Wahl, M. et al., "Effects of Bradykinin on Cerebral Haemodynamics and Blood -Brain Barrier Function", In: Peptidergic Mechanisms in Cerebral Circulation (Edwinssen and McCulloch, Eds.) Chichester, Herwood, pp. 166.
Wahl, M. et al., "Mediators of Blood-Brain Barrier Dysfunction and Formation of Vasogenic Brain Edema", J. Cereb. Blood Flow Metab 634 (1988).
Raymond, J. J. et al., "Pharmacological Modification of Bradykinin Induced Breakdown of the Blood-Brain Barrier", Can. J. Neurol. Sci., 13(3): 214-220 (Aug. 1986).
Saria, A. et al., "Vascular Protein Leakage in Various Tissues Induced by Substance P, Capsaicin, Bradykinin, Serotonin, Histamine and by Antigen Challenge", Naunyn-Schniedeberg's Arch. Pharmacol., 324:2 (1983).
Marceau, F. et al., "Pharmacology of Kinins: Their Relevance to Tissue Injury and Inflammation", Gen. Pharmacol., 14(2): 209-229.
Rhaleb, N.-E. et al., "Structure-Activity Studies on Bradykinin and Related Peptides: Agonists", Br. J. Pharmacol., 99(3) : 445-448 (1990).
Alkermes, Inc.
Davenport Avis M.
LandOfFree
Method for increasing blood-ocular barrier permeability with per does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for increasing blood-ocular barrier permeability with per, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for increasing blood-ocular barrier permeability with per will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1991321